Last reviewed · How we verify
Nucala
At a glance
| Generic name | Nucala |
|---|---|
| Also known as | Mepolizumab |
| Sponsor | Mayo Clinic |
| Target | Interleukin-5 |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Approved indications
- Allergic granulomatosis angiitis
- Asthma
- Eosinophilic asthma
Common side effects
- Headache
- Injection site reaction
- Back pain
- Fatigue
- Influenza
- Urinary tract infection
- Abdominal pain upper
- Pruritus
- Eczema
- Muscle spasms
- Abdominal pain
- Allergic rhinitis
Serious adverse events
- Herpes zoster
- Systemic allergic/hypersensitivity reactions
- Systemic non-allergic reactions
Key clinical trials
- Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab) (PHASE4)
- Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
- NUCALA® Special Drug Use Investigation (EGPA, Long-term)
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (PHASE3)
- Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
- Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease (PHASE2)
- Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA (PHASE4)
- The Role of IL5 in Epithelial Cell Integrity (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |